Trial Profile
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Ages 65 and Under: A Trial Enrolling Subjects to Standard Total Therapy 3 (S-TT3)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Thalidomide (Primary) ; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Lenalidomide; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms TT4B
- 07 Aug 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
- 07 Aug 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.
- 12 Sep 2022 Planned End Date changed from 1 Sep 2022 to 1 Sep 2023.